Pivot Device – Talk Bio

Actionable Insights Powered by AI

Teva plots thousands of job cuts as restructuring drive enters ‘acceleration’ phase

1 day ago talkbio0Tagged 8, Biological Factors, Financial cost, Financial savings, generics, Investments, Operational streamlining, Pivot Device, R&D, Strategic Overhaul, Workforce reduction

Workforce reduction (8%), $700 million cost savings, Strategic overhaul, Generics to biopharmaceuticals pivot, Operational streamlining, R&D investment